Literature DB >> 12506014

Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk.

Alisa S Wolberg1, Dougald M Monroe, Harold R Roberts, Maureane Hoffman.   

Abstract

Individuals with elevated prothrombin levels are at increased risk of venous thrombosis. To understand the mechanism behind this observation, we studied the effect of prothrombin concentration on thrombin generation and fibrin clot structure. The pattern of thrombin generation was directly related to the prothrombin level at all concentrations tested. From 0% to 300% of normal plasma levels of prothrombin, increasing the prothrombin concentration increased the initial rate, peak, and total amount of thrombin generated. Importantly, fibrin clot structure was also affected by the prothrombin concentration. Fibrin clots made from prothrombin concentrations less than 10% of plasma levels were weak and poorly formed. Fibrin clots made at 10% to 100% of plasma levels of prothrombin had similar fiber structures (mass-to-length ratio; mu). However, the fiber mass-to-length ratio decreased with increasing prothrombin levels more than 100% of plasma levels, in a dose-dependent manner. These results suggest that increased levels of prothrombin alter thrombin generation and clot structure. Specifically, elevated prothrombin levels produce clots with reduced fibrin mass-to-length ratios compared with normal clots. We hypothesize that this alteration in fibrin clot structure is an important determinant of the risk of thrombosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506014     DOI: 10.1182/blood-2002-08-2527

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

Review 2.  Fibrinogen and red blood cells in venous thrombosis.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Alisa S Wolberg
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

3.  Effect of blood microparticles on the kinetics of polymerization and enzymatic hydrolysis of fibrin.

Authors:  R M Nabiullina; I G Mustafin; Y F Zuev; D A Faizullin; R I Litvinov; L D Zubairova
Journal:  Dokl Biochem Biophys       Date:  2015-07-12       Impact factor: 0.788

Review 4.  New findings on venous thrombogenesis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Hamostaseologie       Date:  2016-11-23       Impact factor: 1.778

Review 5.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 6.  Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.

Authors:  Alisa S Wolberg; Maria M Aleman; Karin Leiderman; Kellie R Machlus
Journal:  Anesth Analg       Date:  2011-11-21       Impact factor: 5.108

Review 7.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

8.  Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.

Authors:  James R Byrnes; Cédric Duval; Yiming Wang; Caroline E Hansen; Byungwook Ahn; Micah J Mooberry; Martha A Clark; Jill M Johnsen; Susan T Lord; Wilbur A Lam; Joost C M Meijers; Heyu Ni; Robert A S Ariëns; Alisa S Wolberg
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

9.  Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitation.

Authors:  Nathan J White; Erika J Martin; Donald F Brophy; Kevin R Ward
Journal:  Resuscitation       Date:  2009-10-24       Impact factor: 5.262

10.  Polyphosphate enhances fibrin clot structure.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.